Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 1;201(9):1120–1134. doi: 10.1164/rccm.201910-1975OC

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 by the American Thoracic Society

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

PMC Copyright notice

Figure 7. — (A–C) Effects of IGF-1 (insulin-like growth factor-1) treatment on RV hypertrophy (A) and lung function (B and C) in infant rats after antenatal endotoxin (ETX) injection in experimental chorioamnionitis rhIGF-1 (recombinant human IGF-1)/BP3 (binding peptide 3) treatment causes dose-related improvement in RV hypertrophy, total respiratory system resistance (B), and compliance (C). Box plots represent median, interquartile range, and minimum–maximum data points. Animal numbers per study group: control rats = 20; ETX = 19; rhIGF-1/BP3 0.02 mg/kg = 10; 0.2 mg/kg = 18; 2 mg/kg = 19; and 20 mg/kg = 8. LV+S = left ventricle plus septum; RV = right ventricle.